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Abstract 
Literature reports of the efficacy of para-sulfonatocalix[6]- and calix[8]-arenes as U(VI) 
complexants indicated that they might be useful for in vivo chelation of the novel 
therapeutic alhpa-emitter 230U. We have studied the complexation of U(VI) with para-
sulfonatocalix[6]arene and para-sulfonatocalix[8]arene by time resolved laser induced 
fluorescence spectroscopy and using competition methods with Chelex resin and 4-(2-
pyridylazo)resorcinol in simplified and in biological media. New thermodynamic 
parameters describing the stability of U(VI)-para-sulfonatocalix[n]arene [n = 6, 8] 
complexes were obtained. Although the interactions are strong, the complexes do not 
exhibit sufficient stability to compete with carbonate ions and serum proteins for 
complexation of U(VI) under physiological conditions. 
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Introduction 
The alpha emitter 230U (t1/2 = 20.8 d) is a promising novel therapeutic radionuclide for 
application in targeted alpha therapy (TAT) of cancer 1-3. Its decay generates a highly 
cytotoxic cascade of 5 alpha particles with a cumulative energy of 33.4 MeV. The 
principle of targeted alpha therapy (TAT) is based on the stable binding of alpha emitting 
radionuclides to cancer selective carrier molecules, such as antibodies or peptides, via 
bifunctional chelating agents (BCAs). Due to the short range (< 100µm) and the high 
linear energy transfer (≈100 kev/µm) of alpha radiation in human tissue, TAT allows to 
selectively deliver a highly cytotoxic radiation dose to targeted cells while sparing 
surrounding healthy tissue 4. For safe therapeutic application of 230U in targeted therapy, a 
chelating agent is required to link the radiometal to biological carrier molecules in a stable 
manner, since release of the alpha emitter from the radioconjugate in vivo might cause 
toxicity to normal organs. Ideally, a suitable chelating agent should form uranium 
complexes of higher stability than ligands competing for uranium complexation under 
physiological conditions, such as carbonate and proteins 5. Due to the relatively long half-
live of 230U of 20.8 days, the radioconjugate should show high stability over extended 
time periods. 
The "uranophiles" para-sulfonatocalix[6]-arene (L6) 6 and para-sulfonatocalix[8]arene 
(L8) 7 seem promising to meet these requirements, as they have been reported to exhibit 
large stability constants for complexation of uranium(VI). In addition, calixarenes can 
easily be bi-functionalised at the upper rim 8 to be linked to biological carrier molecules 
without modifying the functional groups available at the lower rim for the complexation 
of the metal ion (Fig. 1). Unfortunately, the thermodynamic data on the stability of the 
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complexes of L6 and L8 available in literature are few and vary significantly 6-7, 9-11. 
The aim of the present work was to derive a set of reliable quantitative parameters 
describing the complexation of U(VI) with L6 and L8 and to assess their potential for 
application in TAT, i.e. whether they form uranyl complexes of sufficient stability in 
human blood serum, when the concentrations of both the metal ion and the bifunctional 
ligand are strongly diluted and competing ligands are present in high excess.  
To address these questions, the complexation of uranium(VI) with L6 and L8 was 
investigated by time resolved laser induced fluorescence spectroscopy (TRLFS) and 
competition methods using absorption spectroscopy and sorption to Chelex resin. Based 
on the parameters derived for U(VI)/para-sulfonatocalixarene interaction, and using 
literature data on the interaction of U(VI) with serum components 5, the stability of U(VI)-
para-sulfonatocalixarene complexes under blood serum conditions was modelled and 
compared with experimental data obtained in human blood serum using Chelex column 
chromatography. 
 
Results and discussion 
Interaction of U(VI) with the competing agents 4-(2-pyridylazo)resorcinol (PAR) and 
Chelex resin 
Competition methods are ideal for the quantitative determination of the equilibrium 
constants of ligands with strong uranyl binding properties. However, the reliability of the 
obtained quantitative parameters depends on the constants describing the interaction 
between U(VI) and the competing agent. Therefore, interaction of U(VI) with PAR and 
the functional groups of the Chelex chelating resin was carefully studied. 
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U(VI) complexation with PAR 
The method was used at physiological pH of 7.3 ± 0.1. In the UV/Vis absorption 
spectrum, the formation of the U(VI)-PAR complex is characterized by the appearance of 
an absorption band at λmax = 520 nm (ε = 2.7 × 104 L mol-1 cm-1) and by the decrease of 
the absorption band of the free ligand at λmax = 413 nm (ε = 3.3 × 104 L mol-1 cm-1) (Figs. 
2A and 2B). Both bands were used to characterize the complexation reaction. The 
existence of an isosbestic point indicates that only one U(VI)-PAR complex needs to be 
considered in the modelling approach. U(VI) complexation with PAR was studied as a 
function of total U(VI) (Fig. 2C) or PAR (Fig. 2D) concentration. The experimental data 
could be well explained through the formation of  complex between one U(VI) cation and 
one PAR molecule. According to the data reported for other +2 metal ions 12, the 
formation of an 1:1:0 complex was considered in the modeling, where 0 indicates that the 
deprotonated ligand interacts with U(VI) (see the “modelling approaches” part for a 
detailed explanation on how the equilibria are considered). The experimental data could 
be well described with log β1:1:0 = 16.1 (Table 1). This value is significantly higher than 
the conditional constant reported by Blake et al. 13 (log β = 6.4) obtained under similar 
experimental conditions. The difference can be explained by the fact that the authors used 
a Langmuir-type model and did not take into account the speciation of U(VI) and PAR, 
i.e. the complexation of U(VI) with hydroxide and carbonate ions and the degree of 
deprotonation of PAR.  
 
U(VI) interaction with Chelex 100 
The influence of both pH and uranyl concenration on sorption to Chelex resin is shown in 
Fig. 3. The analysis of the sorption isotherm yields a site capacity of 0.4 meq/g of dry 
resin (Fig. 3B). The sorption was found to be strong in the pH range studied with Kd 
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values higher than 104 L/kg for trace U(VI) concentrations. Two species must be 
considered to describe the sorption behaviour; the 1:1:1 dominates the sorption below pH 
4, while the 1:1:0 species is predominant between pH 4 and 7 (see species distributions in 
Fig. 3A). The decrease in Kd value above pH 6 can be explained by the competition 
between Chelex-100 resin and OH- for complexation of U(VI). The quantitative 
description was performed with the parameters given in Table 1. The data are in good 
agreement with a study made with the model sub-unit N-methyl iminodiacetic acid 14: a 
1:1:0 species was characterized in the pH range 4.5−6.5 with a complexation constant of 
1010.55 (recalculated at zero ionic strength), compared to a value of 1010.85 for the Chelex-
100 resin found in this study. 
 
U(VI) complexation with L8 
The formation of a binuclear complex 2:1 between U(VI) and L8 has been shown in 
solution by a continuous variation method 7,9-10 and has been characterized in the solid 
state by X-ray diffraction (XRD) with the para-tert-butyl derivative of L8 15. This 
stoichiometry was therefore assumed for our calculations. The number of protons involved 
in the equilibrium (z, see eq. (3)) was assessed by studying the pH dependence of Kd using 
the competition method with Chelex-100 (Figs. 4A and B). Assuming the existence of a 
2:1:-3 species as reported by Sonada et al. 10 (Table 1), the prediction of the competition 
between L8 and Chelex-100 does not agree well with the experimental data (dashed lines). 
However, a good agreement is obtained when the formation of a 2:1:0 species 7,9 with a 
stability constant of 1031.4 is considered (solid lines). This constant also allows to describe 
the titration study performed at pH 5.7 (Fig 4C) and is in good agreement with the one 
obtained from the competition study using PAR (1030.5, Fig. 4D, Table 1).  
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U(VI) complexation with L6  
According to the literature 6,9, U(VI) and L6 form complexes with a stochiometry of 1:1; 
therefore x and y were set to 1 in our calculations. Data given by Shinkai et al. obtained at 
pH 10.4 were considered in the data analysis (Fig. 5A). The competition between PAR 
and L6 for U(VI) was studied at pH 7.4 (Fig. 5B). The effect of pH was studied by Time 
Resolved Laser Induced Fluorescence Spectroscopy (TRLFS) in the pH range 4−8 (Fig. 
5C).  
First, the model of Shinkai et al. was tested, considering the formation of a 1:1:0 species 
with a stability constant of 1019.7. However, the modelling results do not agree with our 
experimental data. The complexation of U(VI) with L6 is systematically overestimated 
(dotted lines). 
Secondly, the model of Sonoda et al. was tested: the 1:1:-3 complex is the dominant 
species at pH above 10, 1:1:-2 and 1:1:-3 complexes coexist in the pH range 6-10 and 
1:1:-1 and 1:1:0 complexes are formed below pH 6 (supplementary information, Fig. SM-
1A). The competition between carbonate ions and L6 for complexation of U(VI) studied at 
pH 10.4 by spectrophotometry in the work of Shinkai et al. is therefore a direct evidence 
of the formation of the 1:1:-3 complex. The quantitative analysis of the data gives a 
constant in good agreement with the one determined by potentiometric titration by Sonoda 
et al. (see Table 1). Considering the different methodologies used, this confirmed the 
reliability of the obtained constant. The 1:1:-3 complex contributes to the speciation at 
physiological pH, but at the same time the 1:1:-2 complex is present (see Fig. SM-1A). 
The constant characterizing the formation of the 1:1:-2 complex has therefore been 
deduced from the data obtained at pH 7.4 using the competition method with PAR (Fig. 
5B) while fixing logβ11-3 to that determined above. A good agreement between the 
calculation and the experimental data is found provided that logβ11-2 is increased with 
 7
respect to the data given by Sonoda et al. (see Table 1). The two constants previously 
determined (for 1:1:-2 and 1:1:-3 complexes) were then used together with those given by 
Sonoda et al. 11 for 1:1:0 and 1:1:-1 species to predict the pH dependence studied by 
TRLFS between pH 4 and 7. The results presented in Fig. 5C show that the agreement 
between the experimental data and the prediction (solid line) is satisfactory. In the 
conditions of the present study and using the constant determined from Fig. 5B for 1:1:-2 
complex, 1:1:0 and 1:1:-1 species do not significantly contribute to the complexation of 
uranyl ion (less than  3 %, see Fig. SM-2 in the supplementary information).  
 
Stability of U(VI) complexes with L6 and L8 under blood serum conditions  
In order to evaluate the stability of U(VI)-para-sulfonatocalixarene complexes under blood 
serum conditions, an experimental approach is required that allows to distinguish between the 
fraction of U(VI) complexed with L6 or L8 and the fraction of U(VI) that has been released 
from the para-sulfonatocalixarene complex and is bound to carbonates and/or the protein 
pool, which are the major competing components for uranium binding in blood serum 5. In the 
present work, the distinction was achieved based on the differences in lability of the 
complexes using Chelex column chromatography. Under blood serum conditions, U(VI) is 
mainly complexed by carbonate, human serum albumin and transferrin 5. It was found that 
these complexes are not stable enough to compete with a high excess of Chelex resin, i.e. 
when passing a solution of uranyl ion equilibrated in blood serum through a Chelex-100 
column, only 13 ± 4% (n=9) of U(VI) were eluted through the column, while the remaining 
major fraction of U(VI) was sorbed to the resin. However, when U(VI) is complexed with L6 
or L8, typically less than 20% of U(VI) are sorbed on the resin (Table 2) whereas the 
calculation based on thermodynamic data predicts a complete sorption. The complex is 
therefore sufficiently kinetically stable over the time of the experiment (a few minutes) to 
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avoid any significant decomplexation, probably because of macrocyclic structure of the ligand 
7. 
After complexation of U(VI) with L6 or L8 in HEPES buffer at physiological pH, the stability 
of the formed complexes was followed after dilution in 0.9 % NaCl or human blood serum. In 
agreement with the model calculations, while no significant decomplexation is expected in 0.9 
% NaCl in equilibrium with atmospheric CO2, U(VI)-L6/U(VI)-L8 complexes were found to 
be rapidly dissociated in blood serum at carbonate concentrations of 25 mmol/L. 
 
Discussion 
We report a set of parameters describing the complexation of U(VI) with para-
sulfonatocalix[6]arene based on the model of Sonoda et al. 11. These parameters enable 
the  results obtained using different methods over a wide range of pH (3.5−11) to be 
explained. Assuming the commonly observed pseudoplanar hexa- or penta-dendate 
coordination geometry for uranyl ion, and considering that the sulfonato groups are not 
involved in the interaction, the metal ion would be bound by two deprotonated –OH 
groups and four or three water molecules, the latter undergoing progressive deprotonation 
with increase in pH. This is consistent with the form of the 3:3 U(VI)-L6 complex 
characterized by XRD, where the calixarene acts as a bidentate ligand 16. However, it 
cannot be excluded that the proton release observed at increasing pH is due to the 
dissociation of phenolic hydroxyl groups (presenting no initial acid-base properties in the 
pH range investigated) arising from a metal ion-induced calixarene reorganization 11. In 
agreement with this model, a four-fold deprotonated calixarene moiety was characterized 
by XRD in the case of the 2:2 complex providing each uranyl ion with a close-to-
octahedral coordination 17. The significant difference between our findings and the model 
of Sonoda et al. 11 is the increase of the equilibrium constants for the 1:1:-3 and 1:1:-2 
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complexes, which are the species governing U(VI) speciation at physiological pH. The 
evaluation of the data of Sonoda et al. 11 shows some inconsistencies. According to the 
paper, the authors do not take into account the possible formation of hydroxo species in 
the data evaluation. This would be a viable assumption only if the complexation strength 
of L6 was strong enough to avoid hydrolysis of U(VI). The data were reevaluated using 
the thermodynamic database of Guillaumont et al. 18 (supplementary information, Fig. 
SM-1). If the assumption is valid above pH 6, where the species 1:1:-3 and 1:1:-2 are 
present, this is not the case in the pH range 3−6 where 1:1:0, 1:1:-1 and 1:1:-2 species 
prevail, i.e. as much as 17 % of U(VI) is predicted to exist as polynuclear hydroxo 
species. They account for the proton mass balance and the constants of 1:1:0, 1:1:-1 and 
1:1:-2 complexes obtained by potentiometric titration are therefore underestimated. 
Another reason which would explain this underestimation is related to the slow kinetics 
characterizing U(VI)/L6 interaction, which has also been observed in the current work. As 
pointed by out by Shinkai et al. 6, this limits the applicability of the potentiometric 
titration method as equilibrium conditions may not be reached, but this point was not 
discussed in the work of Sonoda et al. 11. 
The model of Shinkai et al. significantly overestimates the stability of the 1:1:0 complex. 
Assuming the stability constant reported by Shinkai et al., U(VI) should be quantitatively 
complexed by L6 under blood serum conditions (data in parenthesis in Table 2), while our 
experimental tests show a rapid complete dissociation of the complex upon introduction 
into serum media. In line with the report of Harrowfield 16, the ideal preorganisation of L6 
–OH sites for U(VI) postulated by Shinkai et al. 6 to explain this high stability constant is 
not likely: L6 is unable to adopt a conformation in which it encircles the linear uranyl ion 
to get the preferred pseudoplanar hexa- or pentadendate coordination geometry. As 
discussed above, additional ligands (H2O, OH-) are rather involved to complete the 
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coordination sphere. 
In the case of U(VI) complexation by L8, the pH dependence shows the existence of the 
2:1:0 complex instead of the 2:2:-3 proposed by Sonoda et al. 10. This is in agreement with 
the crystallographic structure obtained with the p-tert-butylcalix[8]arene where the 
ligands acts as a tetraanion 15. The stability constant obtained by two independent 
experimental methods is lower than the one proposed by Archimbaud et al. 9 and 
Nagasaki et al. 7. A detailed examination of the data of Nagasaki et al. does not confirm 
the reported constant. The authors considered in the modeling only the presence of CO32-, 
whereas a significant amount of HCO3- exists (about 40 %) under their experimental 
conditions. The given logβ210 is thus overestimated and a value of logβ210= 37.1 (at zero 
ionic strength) was recalculated. This correction however does not significantly change 
the constant and the former remains six order of magnitudes higher than the one 
determined in our work using two different methodologies in a wide range of 
experimental conditions. Furthermore, similarly as for L6, our model confirmed that L8 
cannot compete with proteins and carbonate for complexation of U(VI) in serum media as 
shown by in vitro tests, whereas the model of Nagasaki et al. predicts a significant in vitro 
stability of U(VI)-L8 complex (see data in parenthesis in Table 2). 
 
Experimental 
Reagents and conditions 
The stock solution of natural uranium(VI) was prepared by dilution of a standard solution 
(SPEX CertiPrep® Single-element Solution Standard, U = 1000 μg/mL, 2 % HNO3) with 
addition of sodium hydroxide to obtain a final uranium concentration of 1 × 10-3 M at pH 
~ 3. For radiotracer experiments, either 230U (t1/2= 20.8 d) or 237U (t1/2= 6.75 d) were used. 
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230U was produced via proton irradiation of natural 232Th at the cyclotron of JRC-IHCP, 
Ispra, according to the reaction 232Th(p,3n)230Pa(β-)230U 3 and separated from irradiated 
targets using a combination of extraction chromatography and sorption to silica gel. 237U 
formed from alpha decay of 241Pu (t1/2= 14.35 y) was separated from a plutonium stock 
solution using extraction chromatography as described in 19. Radioactivity measurements 
of 230U and 237U were performed by high resolution gamma spectrometry (HRGS) using a 
calibrated HpGe well detector connected to a 92X spectrum master multi-channel analyzer 
(EG&G Ortec). 237U was analysed via the 59.5 keV gamma emission (34% emission 
probability). Activity of 230U was analysed using the 111 keV gamma emission (3.2% 
emission probability) of its daughter nuclide 226Th after radiochemical equilibrium was 
reached, typically after 1 day. 
A stock solution of 8.4 × 104 M PAR (4-(2-pyridylazo)resorcinol, p.a., Fluka)  was 
prepared by dissolution of PAR in 0.05 M TRIS (tris(hydroxymethyl)aminomethane) 
buffer. A stock solution of 10-2 M L6 (para-sulfonatocalix[6]arene hydrate, 95%, Acros 
Organics) was prepared by dissolution of L6 in 0.9% NaCl, filtered through 0.22 μm filter 
cartridges (Whatman, Spartan-HPLC Syringe filters) and used for further dilutions. A 
stock solution of 0.12 M L8 (para-sulfonatocalix[8]arene hydrate, containing 20% water, 
TCI Europe) was prepared by dissolution of L8 in 0.9% NaCl and filtered as described 
above.  
Chelex-100 extraction resin (sodium form, 50-100 mesh (dry), Sigma) was washed several 
times with Milli-Q water until neutral conditions and conditioned with 0.9% NaCl prior to 
use. For serum stability studies, 0.5 mL of wet resin was loaded in polypropylene 
chromatographic columns (Bio-Spin, Bio-Rad Laboratories, Inc.) and covered with quartz 
wool. 
For the preparation of human blood serum, blood samples were collected from healthy 
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volunteers into Vacutainers containing EDTA as anticoagulant (0.2 % in weight). A 
simulation made with the parameters quantifying U(VI)/EDTA28 and U(VI)/serum 
components5 interaction showed no effect of the presence of the chelating agent on U(VI) 
speciation. Serum was separated from blood cells by centrifugation, stored at -20 °C, and 
brought to room temperature immediately before use. All other chemicals were reagent 
grade and all solutions were prepared in Milli-Q water. Experiments were performed at 
room temperature (23 ± 3 °C) in the pH range 4−11 at an ionic strength of 0.1 (NaCl or 
NaClO4) under normal atmosphere. 
 
Investigation of interactions of U(VI) with para-sulfonatocalixarenes  
Considering the high complexation strength of L6 and L8 with U(VI), competition 
methods were used to study the complex formation. The species distribution of U(VI) was 
determined based on sorption to Chelex chelating resin followed by phase separation 
(CM-Chelex) or by spectrophotometric detection in the presence of PAR as competing 
ligand (CM-PAR). In the case of L6, TRLFS was used as a third independent method. All 
solutions/suspensions used for the sorption/complexation studies were prepared well in 
advance to allow for equilibration with atmospheric CO2. 
 
Competition method with Chelex-100 resin (CM-Chelex) 
Chelex-100 is a strong chelating resin containing iminodiacetic acid groups as active 
goups. Experiments were performed based on a classical batch method. A pre-
equilibration of solid and liquid phases was performed before addition of U(VI) (i.e. the 
solution composition is expected not to vary in the presence of the solid during the 
adsorption experiments). After addition of U(VI), solutions were left to equilibrate (< 12 
h), followed by addition of the competing ligand. The system re-equilibration was found 
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to be relatively slow, i.e. at least 2 days and 12 hours were necessary for L6 and L8, 
respectively. The separation between liquid and solid phases was performed by 
centrifugation. The sorption of U(VI) on Chelex was expressed by Eq. (1): 
S
L
A
AA
K
L
Ltot
d ⋅−=
    (1)
 
where Kd is the distribution coefficient, Atot is the overall activity added to the system (Bq), 
AL is the equilibrium activity in the liquid phase (Bq), and S/L the solid to liquid ratio in kg/L. 
To exclude effects of adsorption of the metal ion to the walls of the vials, Atot was determined 
by analysing the uranium activity of an aliquot of the suspension. Preliminary experiments 
showed that the sampling of the suspension was homogeneous. 
 
Competition method with PAR (CM-PAR) 
Competition experiments with PAR were performed at the pH of human blood serum (pH 
7.3 ± 0.1). Solutions containing U(VI) and PAR were equilibrated for 1 min before 
addition of the competing ligand. The re-equilibration time was shown to be fast (less than 
15 min). Spectra were recorded on a Ultrospec™ 2100 pro UV/Visible spectrophotometer 
in the wavelength range from 300-600 nm. 
 
Time Resolved Laser Fluorescence Spectroscopy (TRLFS) 
Details concerning the spectroscopic device as well as details on how spectroscopic data were 
obtained are described in. 20 U(VI) was excited at a wavelength of 430 nm with a laser 
intensity of about 3 mJ. U(VI) complexation by L6 leads to a complete extinction of the 
fluorescence signal. This extinction cannot result from absorption processes, as negligible 
absorption coefficients at the excitation (430 nm) and the fluorescence emission (460-600 nm) 
wavelengths were observed for L6. In given experimental conditions, and considering a static 
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quenching phenomenon, the percentage of U(VI) not bound to L6 can be determined 
according to Eq. (2): 
totFI
FI))VI(U%( =      (2) 
FItot and FI correspond to the fluorescence intensity measured before and after addition of 
L6, respectively. 
 
Serum stability studies 
The stability of U(VI)-L6 and -L8 complexes in human blood serum was studied using a 
Chelex-100 column method. For the separation of U(VI)-para-sulfonatocalixarene 
complexes from uranium species not bound to para-sulfonatocalixarene (i.e. uranium 
bound to carbonate or serum proteins), an aliquot of sample solution was loaded on the 
column and subsequently the column was washed with 3 mL 0.9% NaCl to elute U(VI)-
para-sulfonatocalixarene complexes (fraction 1). “Non-calixarene-complexed” uranium 
was retained on the column and was subsequently eluted from the column with 3 mL 1 M 
HCl (fraction 2). Both fractions were measured by HRGS and activity of 230U in each 
fraction was expressed as % of total activity. Blank runs were performed to determine the 
recovery of "calixarene-bound" and "non-calixarene-bound" uranium in fractions 1 and 2, 
respectively. For serum stability studies, complexation of 230U with L6 or L8 was 
performed in HEPES buffer by stepwise addition of the minimum amount of ligand 
required to achieve > 80% complexation after equilibrium was reached. Subsequently, the 
sample was divided and diluted with 0.9% NaCl (served as a reference) or human blood 
serum (see conditions in Table 2) and the fraction of para-sulfonatocalixarene-bound 
uranium was analysed at regular time intervals as described above. 
  
Modelling approaches 
 15
Complexation in solution 
The interaction between the metal ion (M) and the ligand (L) is described by the following 
equilibrium as presented in Eq.(3): 
++−→←++−++ z)ny(mxzHyLxM  zHnyLmxM     (3) 
with n corresponding to the number of acid protons presenting acid-base properties, z the 
number of protons involved in the reaction, x the number of metal ions complexed and y 
the number of ligands complexing M. The associated stability constant is defined by 
Eq.(4): 
z)(Hy)n(Lx)m(M
)z)ny(mxzHyLx(M
xyzβ +−+
++−
=     (4) 
Where (i) represents the activity of species i. All ionic strength corrections were done 
using the Davies equation 21. 
In the case of PAR, z = 2 with pKa values of 5.56 and 11.98 (0.1 M ionic strength) 12. 
Based on the XRD structures obtained with the para-t-butylcalixarenes and U(VI) 15-17, we 
assume that U(VI) interacts with the hydroxyl groups of the ligands and that the sulfonato 
groups are not involved in the complexation. L6 has two ionizable OH groups 22,11 in the 
pH range generally considered for complexation studies (pH 3−12). pKa values were taken 
from 11, i.e. 3.28 and 4.86 (0.1 M KNO3, 25 °C). L8 can be viewed as two tetrameric units 
originating from the pinched conformation as fairly independent from one another 22. For 
each tetrameric unit, two types of hydroxyl groups were observed: one acidic type and one 
which dissociates in the alkaline region. pKa values of 3.73, 4.39, 8.07 and 10.1 (0.1 M 
KNO3, 25 °C) were taken from Sonoda et al. 10 When the mass balance of the reaction 
indicates that more protons are produced than consumed 10,11, we consider that they arise 
from the complexation of uranyl hydroxo species as presented in Eq.(5): 
+++−−→←+−++ zHz)ny(mxzOHyLxM  O2zHnyLmxM      (5) 
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The equilibrium constants describing the interaction between U(VI) and inorganic ligands 
(chloride, carbonate, hydroxide) were taken from Guillaumont et al. 18. Carbonate 
concentration, unless fixed, was calculated considering an equilibrium with atmospheric 
CO2 (pCO2 = -3.5). All the calculations were done using the simulation code PHREEQC, a 
modelling code for aqueous systems 23. 
 
U(VI) sorption on Chelex 
Chelex resin is a styrene divinylbenzene copolymer containing iminodiacetic acid 
chelating groups. The resin is considered to act as a "solid complexing" agent, i.e. the 
reactions characterizing the interaction in solution (acid properties, complexation 
reaction) are supposed to occur at the resin surface. The surface complexation model 
developed for surfaces of oxides was used 24 and Eq. (3−5) are therefore applicable. The 
most important difference between complexation of U(VI) with ligands in solution in 
comparison to complexation with Chelex resin is that in the case of the resin, the ligand is 
bound on a solid support and the dependence of the complexation strength on the ligand 
concentration is not the same. Furthermore, the activity coefficient correction is different 
if the ligand is free or bound. When the ligand is bound, an electrostatic effect should be 
considered because of the surface charge 25, e.g. using one of the models developed for 
oxides available in the PHREEQC code. However, the most significant difference between 
Chelex resin and sorption on the oxides is that Chelex resin swells as the pH increases 
(protons are replaced by Na+ ions) 26. This leads to a change of the specific surface and 
does not allow a simple correction for the electrostatic term to be made. The electrostatic 
effects were therefore neglected in this study, i.e. the activity coefficient of the bound 
species is equal to 1. Acid-base properties of the resins were investigated previously 25, 27. 
The authors came to the conclusion that the pKa values are in agreement with those 
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reported for the two model ligands, the benzyl- and methyl-iminodiacetic acids. In the 
present study, published pKa values of N-benzyl-iminodiacetic acid were used (2.21 and 
8.9, 0.1 M ionic strength, 25 °C) 28. 
 
Conclusions 
A new set of parameters is reported to describe U(VI) interaction with L6 and L8. 
Contrary to what is stated in the literature, L6 cannot be considered as a super-uranophile 
as its structure is not ideally pre-organized for U(VI) complexation. L8 can accommodate 
two uranyl ions without other synergistic anions in the first coordination sphere. Both 
simulation and experimental data show that L6 and L8 are not suited for TAT applications 
due to the low stability of their U(VI) complexes under blood serum conditions where the 
expected ligand concentrations would be less than 10-8 M. 
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CM competition method 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
L6 para-sulfonatocalix[6]arene 
L8 para-sulfonatocalix[8]arene 
PAR 4-(2-pyridylazo)resorcinol 
TRIS tris(hydroxymethyl)aminomethane 
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TRLFS  time-resolved laser-induced fluorescence spectroscopy 
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Table 1. Quantitative description of the complexation of U(VI) with PAR, Chelex resin, L6 and L8. 
 
  Number of complexes complex x:y:z log βxyz  Note Conditions Method Ref 
PAR 1 1:1:0 † 16.1 ± 0.3 _ 0.1 M NaCl, pH 7.3±0.1 Spectrophotometric determination this work 
1:1:1 6.0 ± 0.2 Chelex-
100 2 1:1:0 10.8 ± 0.3 
_ 0.1 M NaCl,  pH 1.5−7.8 batch experiments this work 
  1:1:0 † 19.7 ± 0.1 re-evaluated at 19.2  0.01 M carbonate, pH 10.4,  I~0.025 M competition method with carbonate 6 
1:1:0 4.33 
1:1:-1 0.39 
1:1:-2 -4.6 
4§ 
1:1:-3 -12.7 
_ 0.1 M KNO3, pH 4−11,  25°C potentiometric titration method 11 
1:1:0 4.33 fixed in the fitting _ _ 
1:1:-1 0.39 fixed in the fitting _ _ 
1:1:-2 -3.4 ± 0.2 log β11-3 fixed at -12.2 0.1 M NaCl, pH 7.4 competition method with PAR 
1:1:-3 -12.2 ± 0.1 Analysis of the data from ref. 6  0.01 M carbonate, pH 10.4,  I~0.025 M competition method with carbonate 
L6 
4 
_ _ 
all parameters fixed  
(logβ11-2 and logβ11-3 fixed to -3.4 
and -12.2, respectively) 
0.1 M NaClO4,  pH 3.5−7 TRLFS 
this work 
1 2:1:0 † 40.8 _ not given not given 9 
1 2:1:0 † 37.6 re-evaluated as 37.1  0.01 M carbonate, pH  10.4,  I~0.025 M competition method with carbonate 7 
1§ 2:1:-3 13.4 _ 0.1 M KNO3, pH 4−11  25°C potentiometric titration method 10 
1 31.4 ± 0.4 _ 0.1 M NaCl,  pH 3−7 Competition method with Chelex-100 
L8 
1 
2:1:0 
30.5 ± 0.3 _ 0.1 M NaCl, pH 7.3±0.1 Competition method with PAR 
this work 
 
§ number of species determined in the pH range of interest of the study (4-11);  
† z=0 is an assumption based on literature data; data in italic: log K values recalculated at zero ionic strength
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Table 2. Serum stability of U(VI)-para-sulfonatocalixarene complexes; comparison 
between experiment and calculation. The data in parenthesis are calculated with the 
parameters given in the literature 6,7. HEPES: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid. 
 
Complex formation dissociation 
Ligand Conditions, 
[U(VI]tot~10-8 M
time % exp % calc conditions time % exp % calc 
4.7 × 10-5 M L6 
pH 7  
0.1 M HEPES 
3.8 h 82 100 (100) 
dilution 1:10 in 
0.9 % NaCl. 
pH 7.6, 37°C 
15 h 85 99 (100) 
L6 
10-5 M  L6, pH 7
0.1 M HEPES 5.8 h 80.5 99 (100) 
dilution 1:10. 
serum, 37 °C 2 h 15 
 
0 (100) 
 
2.1 × 10-5 M L8 
pH 7.6 
1 M HEPES 
10 min 91 99 (100) 
dilution 1:10 in 
0.9 % NaCl. 
pH 7.6, 37°C 
200 h 90 97 (100) 
L8 
2.5 × 10-5 M L8 
pH 7.6  
0.8 M HEPES 
30 min 86.4 99 (100) dilution 2/9. serum, 37 °C 10 h 0 0 (39) 
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Figure 1: Calixarene family and selected calixarenes: L6 (n=6, R=-SO3Na; Y=H) and L8 
(n=8, R=-SO3Na; Y=H). 
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Figure 2: U(VI) interaction with PAR, pH 7.3 ± 0.1, 0.1 M NaCl, 2 × 10-3 M TRIS. (A) 
effect of U(VI) concentration on PAR absorption spectra. (B) Absorption of the complex 
at 520 nm for as a function of U(VI) concentration. The line is calculated with ε = 2.7 × 
104 L mol-1 cm-1 (U(VI)-PAR) at λmax = 520 nm,  [PAR]tot = 4 × 10-5 M. Complexation of 
U(VI) with PAR as a function of uranium concentration (C; circles: [PAR]tot = 3.8 × 10-5 
M, squares: [PAR]tot = 1.6 × 10-5 M) and PAR concenration (D; circles: [U(VI)]tot=1.9 × 
10-5 M; squares: [U(VI)]tot = 3.6 × 10-5 M) concentrations. The filled and open symbols are 
obtained from the absorbance at 520 nm and 413 nm, respectively. The lines are calculated 
with the parameters given in Table 1. 
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Figure 3. U(VI) sorption on Chelex-100 in 0.1 M NaCl (S/L=0.05-1 g/L) as a function of pH 
([U]sol < 10-7 M), (A) and uranium concentration (pH 2.2) (B). The lines are calculated with 
the parameters given in Table 1. 
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Figure 4. Complexation study between L8 and U(VI) using CM-Chelex (A, B, C) and CM-
PAR (D) methodologies. (A) S/L=0.14 g/L, [U(VI)]tot=10-7 M, [L8]tot =3 × 10-8 M. (B) 
S/L=0.5 g/L, [U(VI)]tot=10-7 M, [L8]tot=6 × 10-6 M. (C) S/L=0.14 g/L, [U(VI)]tot=10-7 M, pH 
5.7. (D) [PAR]=1.6 × 10-5 M, pH  7.3, [U(VI)]tot=7.9 × 10-6 M. All experiments were 
performed in 0.1 M NaCl. The dotted lines are the predictions made with the parameters of 
Sonoda et al. 11. The solid lines are calculated with the model presented in this work (Table 
1). 
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Figure 5: U(VI) Complexation by  L6. (A) Data range (dotted lines) calculated based on the 
data of Shinkai et al. 6 (the two lines account for the error associated to the published 
constant) pH 10.4, [K4UO2(CO3)3]=1.51 × 10-3 M, 0.01 M carbonates. (B) Competition 
method with PAR. [PAR]tot=1.5 × 10-5 M, pH 7.4 and [U(VI)]tot=7.9 × 10-6 M; [NaCl]=0.1 M. 
(C) Study as a function of the pH by TRLFS; [NaClO4]=0.1 M, [U(VI)]tot=1.5 × 10-6 M and 
[L6]=10-5 M. The dashed lines are calculated based on the model of Shinkai et al. 6 .The solid 
lines correspond to our model (Table 1). 
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Figure SM-1: Complexation of U(VI) by L6. Speciation diagram as a function of pH 
according to the work of Sonoda et al. 11, considering (B) or not considering (A) the 
formation of hydrolysed species (hyd. Species; notably (UO2)2OH3+ and (UO2)2(OH)22+). 
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Figure SM-2: Complexation of U(VI) by L6. Speciation diagram calculated with the 
parameters determined in this work (Table 1) as a function of the pH in the conditions of 
Figure 5C, i.e. [NaClO4]=0.1 M, [U(VI)]tot=1.5 × 10-6 M and [L6]=10-5 M. 
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